Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The development of biomaterial matrices for xeno-free culture and long-term maintenance of human pluripotent stem cells

EF 2013-14

Résumé
It is estimated that four out of five Canadians are at risk to develop degenerative chronic diseases, including diabetes and heart disease. Pluripotent stem cells (PSCs) show great promise as a potential future therapeutic for these degenerative diseases as stem cells have the ability to contribute to all tissues and organs in the human body, known as pluripotency. One substantial limiting factor in the translation of stem cell therapies from the lab to the clinic, however, is the absence of suitable growth conditions for pluripotent stem cells. Current conditions used to derive and maintain PSCs contain animal products that present a significant risk of viral, bacterial, or parasitic transmission to stem cells. Moreover, these conditions may contain toxic biomolecules that may harm recipients of stem cell therapy. Therefore, there is a great need for a chemically defined culture system free of animal products that eliminates the risk of pathogen transmission to PSCs. To this end, the primary objectives of this study are to i) develop a synthetic, protein-coated biomaterial that supports PSC growth and ii) test this biomaterial’s ability to maintain growth of PSCs and their ability to reconstitute all bodily tissues over long term culture (= 6 months). Six proteins known to be secreted by PSCs in culture and the biophysical properties of the biomaterial will be screened combinatorially to determine which condition best supports PSC growth and expression of pluripotency-maintaining genes. The development of biomaterials from this study that are capable of maintaining growth and pluripotency of PSCs is critical to PSCs reaching their full therapeutic potential. These biomaterial will allow for the pathogen-free derivation and culture of PSCs, leading to the development of safe, clinical grade PSCs in a more cost-effective and reproducible manner. With the advent of patient-specific stem cell lines, biomaterials from our study will aid in establishing personalized stem cell therapies for degenerative diseases that continue to threaten 80% of Canadians.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
312028
Name
Ireland Ronald
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The development of biomaterial matrices for xeno-free culture and long-term maintenance of human pluripotent stem cells
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomaterials; Biomedical Engineering; Cell Culture Technology; Extracellular Matrix; Pluripotent Stem Cells; Regenerative Medicine; Xeno-Free
Abstract
It is estimated that four out of five Canadians are at risk to develop degenerative chronic diseases, including diabetes and heart disease. Pluripotent stem cells (PSCs) show great promise as a potential future therapeutic for these degenerative diseases as stem cells have the ability to contribute to all tissues and organs in the human body, known as pluripotency. One substantial limiting factor in the translation of stem cell therapies from the lab to the clinic, however, is the absence of suitable growth conditions for pluripotent stem cells. Current conditions used to derive and maintain PSCs contain animal products that present a significant risk of viral, bacterial, or parasitic transmission to stem cells. Moreover, these conditions may contain toxic biomolecules that may harm recipients of stem cell therapy. Therefore, there is a great need for a chemically defined culture system free of animal products that eliminates the risk of pathogen transmission to PSCs. To this end, the primary objectives of this study are to i) develop a synthetic, protein-coated biomaterial that supports PSC growth and ii) test this biomaterial’s ability to maintain growth of PSCs and their ability to reconstitute all bodily tissues over long term culture (= 6 months). Six proteins known to be secreted by PSCs in culture and the biophysical properties of the biomaterial will be screened combinatorially to determine which condition best supports PSC growth and expression of pluripotency-maintaining genes. The development of biomaterials from this study that are capable of maintaining growth and pluripotency of PSCs is critical to PSCs reaching their full therapeutic potential. These biomaterial will allow for the pathogen-free derivation and culture of PSCs, leading to the development of safe, clinical grade PSCs in a more cost-effective and reproducible manner. With the advent of patient-specific stem cell lines, biomaterials from our study will aid in establishing personalized stem cell therapies for degenerative diseases that continue to threaten 80% of Canadians.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ireland, Ronald
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~